Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer

Annexin A3 has been demonstrated to be a key pathogenic protein in the occurrence and development of triple-negative breast cancer (TNBC); its overexpression in TNBC cells can promote the proliferation, migration, and drug resistance of TNBC. Previously, we reported the first ANXA3 degrader, (<i&...

Full description

Saved in:

Bibliographic Details
Main Author:	Kunlin Liu (6388580) (author)
Other Authors:	Chenhao Zhu (8962280) (author), Yongxi Liang (5536487) (author), Delin Min (20795184) (author), Zijun Jin (18827377) (author), Xun Sun (364650) (author)
Published:	2025
Subjects:	Biophysics Biochemistry Cell Biology Pharmacology Biotechnology Cancer Infectious Diseases Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified negative breast cancer key pathogenic protein first anxa3 degrader promising lead compound sl18 </ b 18a5 </ b anxa3 binding activity r </ stronger binding functional activity >< b >)-< b target effects structural optimization potent anti obtain molecules lower toxicity fold increase family proteins drug resistance benzodiazepine derivative 96 %).
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer

Similar Items